Hyperbaric Oxygen and Telomeres: What the Tel Aviv Study Found

Facebook ↗WhatsApp ↗

Originally published 2020-11-30.

Hyperbaric-Oxygen Research on Ageing-Related Blood Markers

In November 2020 researchers in Israel reported that a course of hyperbaric oxygen therapy (HBOT) lengthened telomeres and reduced the share of "senescent" immune cells in the blood of older adults. Headlines quickly announced that ageing had been reversed. The real result is narrower: a small trial without a control group found changes in two cellular markers linked to ageing, measured in blood cells only. It is an interesting lead, not proof that anyone became younger or will live longer.

Here is what the study did, what telomeres and senescent cells are, why the findings drew both excitement and scepticism, and what the evidence means for anyone curious about oxygen chambers.

What the study found

The paper, titled "Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial", appeared in the journal Aging on 18 November 2020. The team, from the Shamir Medical Center and Tel Aviv University, was led by Yafit Hachmo, with Amir Hadanny and Shai Efrati among the authors.

Thirty-five healthy, independently living adults aged 64 or older enrolled, with an average age of about 68. Thirty finished the programme. Because of sample quality problems, telomere results were analysed for 25 people and senescent cell results for 20.

Participants had 60 sessions over roughly three months, five days a week. In each 90-minute session they breathed 100% oxygen through a mask inside a chamber pressurised to two atmospheres, with short air breaks. Blood was drawn before treatment, at the 30th and 60th sessions, and one to two weeks after the last one.

The headline numbers:

  • Telomere length in several types of white blood cells rose by roughly 20% to 38% compared with baseline, with the largest change in B cells (about 38% after treatment ended).
  • The proportion of senescent T helper cells fell by about 37% after treatment, and senescent cytotoxic T cells fell by about 11%.

Not every change was statistically solid. The rise in natural killer cell telomeres after treatment narrowly missed significance, and when the researchers analysed all time points together, only the B-cell telomere change was clearly significant.

Telomeres and senescent cells, explained

Telomeres are protective caps of repetitive DNA at the ends of chromosomes, often compared with the plastic tips on shoelaces. Each time most cells divide, the caps get a little shorter. When they become too short, the cell stops dividing or dies. On average, people with shorter telomeres in their blood cells tend to be older and to have higher rates of some age-related diseases, which is why telomere length is used as a rough biological marker.

Senescent cells are cells that have permanently stopped dividing but have not died. They accumulate with age and can release inflammatory signals that affect nearby tissue. In the immune system, a build-up of senescent T cells is part of what scientists call immunosenescence, the gradual weakening of immune responses in later life.

Both markers are useful, but neither is a complete measure of ageing. Telomere length varies widely between people of the same age, differs between cell types, and is tricky to measure. A University of Pennsylvania researcher noted, in comments about a separate telomere claim, that measurements typically vary by around 10% between tests.

Why the researchers were excited

The authors suggested that repeated swings in oxygen levels during and between sessions may trigger some of the same repair signals the body uses when oxygen is scarce. They measured a rise in HIF-1 alpha, a protein involved in that response, during treatment.

Efrati, a co-author, told The Independent that the results show ageing "can, indeed, be targeted and reversed at the basic cellular-biological level." Hadanny said the telomere gains came "at rates far beyond any of the current available interventions or lifestyle modifications," pointing out that exercise and diet studies usually show slower shortening rather than lengthening.

The limitations that matter

The paper itself lists several weaknesses, and they are significant:

  • No control group. Without a comparison group receiving a sham or no treatment, it is impossible to rule out other explanations, such as seasonal effects, lab drift or the extra attention participants received.
  • Small numbers. Results came from 20 to 25 people, after a number of samples were excluded.
  • Blood cells only. The measurements were in circulating immune cells, which turn over relatively quickly. They say nothing directly about the heart, brain, skin or other organs.
  • Short follow-up. Blood was last checked one to two weeks after treatment. Nobody knows if the changes last, and the study did not track health or survival.
  • Mechanism unclear. Telomerase, the enzyme that rebuilds telomeres, was not measured. A rise in average telomere length could also reflect a shift in which cells are circulating rather than caps actually growing.
  • Conflicts of interest. Several authors were affiliated with Aviv Scientific, a company that offers HBOT-based programmes, which the paper disclosed.

None of this means the result is wrong. It means a larger, randomised, controlled trial with longer follow-up and clinical outcomes would be needed before drawing firm conclusions.

Not the first telomere promise

Claims about telomere lengthening have a colourful history. In 2015 Elizabeth Parrish, chief executive of the US start-up BioViva, travelled to Colombia to receive experimental gene therapies on herself, calling herself "patient zero". In 2016 the company released data saying her white blood cell telomeres had lengthened. Critics noted the reported change was about the size of normal measurement variation, and that a single self-experiment cannot show a treatment works. The US Food and Drug Administration had not authorised the experiment.

The lesson is not that every telomere study is hype, but that changes in a biomarker are easy to overstate and hard to translate into longer, healthier lives.

What HBOT is used for today

Hyperbaric oxygen therapy is a well-established medical treatment for specific conditions, such as decompression sickness in divers, carbon monoxide poisoning and certain hard-to-heal wounds. In those settings it is given under medical supervision because pressurised oxygen carries real risks, including ear and sinus injury from pressure changes and, rarely, oxygen toxicity affecting the lungs or nervous system. It is not suitable for everyone.

Private clinics now market HBOT for a much wider range of goals, including "anti-ageing". The 2020 study does not establish that such programmes extend life or improve health in older adults. Anyone considering HBOT should talk to a doctor first.

The bigger picture

If a treatment one day proves it can slow biological ageing in a meaningful way, it will raise questions far beyond medicine: who can afford it, how health systems pay for it, and what longer lives mean for pensions and work. The Tel Aviv trial is a small, early step in that conversation. It showed measurable changes in blood cell markers during an intensive course of oxygen therapy, and it gave other researchers a clear hypothesis to test. For now, the most reliable ways to support healthy ageing remain the familiar ones: not smoking, staying active, sleeping well, eating a balanced diet and keeping up with medical care.

Sources: Hachmo et al., Aging 12(22), 18 November 2020 (full text); The Independent (original reporting and quotes); Wikipedia: BioViva.

COMMENTS